<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vaccine platforms employed for available and candidate COVID-19 vaccines</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vaccine platforms employed for available and candidate COVID-19 vaccines</h1>
<div class="graphic"><div class="figure"><div class="ttl">Vaccine platforms employed for available and candidate COVID-19 vaccines</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Platform type</td> <td class="subtitle1">Description</td> <td class="subtitle1">COVID-19 vaccine examples*</td> <td class="subtitle1">Other vaccine examples</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Whole virus vaccines</td> </tr> <tr> <td class="indent1">Inactivated vaccines</td> <td> <ul> <li>Produced by growing SARS-CoV-2 in cell culture then chemically inactivating the virus.</li> <li>Often combined with an adjuvant to stimulate immune response.</li> </ul> </td> <td> <ul> <li>CoronaVac (Sinovac)</li> <li>BBIBP-CorV/HB02 (Covilo, Sinopharm [Beijing])</li> <li>Covaxin (Bharat Biotech)</li> </ul> </td> <td> <ul> <li>Hepatitis A vaccine</li> <li>Inactivated poliovirus vaccine</li> </ul> </td> <td> <ul> <li>Immune response targets multiple viral antigens.</li> </ul> </td> </tr> <tr> <td class="indent1">Live attenuated vaccines</td> <td> <ul> <li>Produced by developing weakened versions of wild-type SARS-CoV-2 through genetic modification or growth in adverse conditions.</li> </ul> </td> <td> <ul> <li>COVI-VAC (Codagenix/Serum Institute of India) – in early trials</li> </ul> </td> <td> <ul> <li>Measles, mumps, rubella vaccine</li> <li>Varicella vaccine</li> </ul> </td> <td> <ul> <li>Immune response targets multiple viral antigens.</li> <li>Can be administered intranasally and thus might induce mucosal immune response at the site of viral entry.</li> <li>Theoretic concern about reversion to or recombination with wild-type virus.</li> <li>Not appropriate for immunocompromised individuals.</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Viral component vaccines</td> </tr> <tr> <td class="indent1">mRNA vaccines</td> <td> <ul> <li>Consist of mRNA encoding target gene.</li> <li>Once administered, mRNA is translated into target protein, which elicits immune response.</li> </ul> </td> <td> <ul> <li>BNT162b2 (Pfizer-BioNTech vaccine)</li> <li>mRNA-1273 (Moderna vaccine)</li> </ul> </td> <td> </td> <td> <ul> <li>mRNA remains in cell cytoplasm, does not enter nucleus, and does not interact with or integrate into recipient DNA.</li> <li>May require low temperature storage.</li> </ul> </td> </tr> <tr> <td class="indent1">Vector virus vaccines (both replication incompetent and competent)</td> <td> <ul> <li>Uses a different virus (not SARS-CoV-2) as a vector or carrier that expresses the viral protein that is the intended target.</li> </ul> </td> <td> </td> <td> </td> <td> <ul> <li>Pre-existing immunity to the vector can attenuate vaccine immunogenicity (thus, viral vectors that are uncommon in humans, animal virus vectors, or vectors that do not induce self-immunity are preferred).</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Replication-incompetent vector vaccines</li> </ul> </td> <td> <ul> <li>Viral vector has been engineered not to replicate.</li> </ul> </td> <td> <ul> <li>Ad26.COV2.S (Janssen/Johnson &amp; Johnson)</li> <li>ChAdOx1 nCoV-19/AZD1222 (AstraZeneca)</li> <li>Gam-COVID-Vac Sputnik V (Gamaleya Institute)</li> <li>Ad5-nCoV (CanSino)</li> </ul> </td> <td> <ul> <li>Ad26.ZEBOV/MVA-BN-Filo (an Ebola virus vaccine)</li> </ul> </td> <td> <ul> <li>Failure of the vector to reproduce could theoretically reduce potential adverse events that could occur with replicating vectors.</li> <li>Example vectors include adenovirus, modified vaccinia Ankara (MVA), human parainfluenza virus, influenza virus, adeno-associated virus (AAV), and Sendai virus.</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Replication-competent vector vaccines</li> </ul> </td> <td> <ul> <li>Viral vector is derived from attenuated or vaccine strains of viruses.</li> </ul> </td> <td> <ul> <li>DelNS1-2019-nCoV-RBD-OPT1, an intranasal flu-based RBD vaccine (University of Hong Kong) – in trials</li> </ul> </td> <td> <ul> <li>rVSV-ZEBOV (an Ebola virus vaccine)</li> </ul> </td> <td> <ul> <li>Often result in more robust immune response compared with replication-incompetent vectors (stimulate innate immune response).</li> <li>Can be administered intranasally and thus might induce mucosal immune response at the site of viral entry.</li> <li>Example vectors include measles vaccine strains, influenza virus, vesicular stomatitis virus (VSV), and Newcastle disease virus (NDV).</li> </ul> </td> </tr> <tr> <td class="indent1">Recombinant protein vaccines</td> <td> <ul> <li>Composed of purified viral proteins that have been expressed in one of various systems (eg, insect and mammalian cells, yeast cells, plants).</li> </ul> </td> <td> <ul> <li>NVX-CoV2373 (Novavax)</li> </ul> </td> <td> <ul> <li>Human papillomavirus vaccines</li> <li>Hepatitis B vaccines</li> </ul> </td> <td> <ul> <li>Stimulates immunity to the purified viral protein.</li> </ul> </td> </tr> <tr> <td class="indent1">DNA vaccines</td> <td> <ul> <li>Consist of plasmid DNA that contain mammalian expression promotors and the target gene, so that the target protein is expressed in the recipient.</li> </ul> </td> <td> <ul> <li>ZyCoV-D (Zydus Cadila)</li> </ul> </td> <td> </td> <td> <ul> <li>Are often of low immunogenicity.</li> <li>Need special delivery devices (eg, electroporators).</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">* This is not an exhaustive list of example COVID-19 vaccines and vaccine candidates for each vaccine platform. The World Health Organization maintains an <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" target="_blank">updated list of vaccines in development</a>.</div><div id="graphicVersion">Graphic 135003 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
